|
gptkbp:instance_of
|
gptkb:virus
|
|
gptkbp:antiviral_therapy
|
can reduce liver damage
|
|
gptkbp:cause
|
gptkb:virus
|
|
gptkbp:cdc
|
gptkb:Centers_for_Disease_Control_and_Prevention
|
|
gptkbp:chronic_carriers
|
can transmit virus
|
|
gptkbp:clinical_trial
|
in progress
|
|
gptkbp:community_health
|
important issue
impact prevention efforts
|
|
gptkbp:community_outreach
|
important for education
|
|
gptkbp:customs
|
associated with infection
|
|
gptkbp:data_usage
|
high in endemic areas
|
|
gptkbp:diagnosis
|
blood test
|
|
gptkbp:diseases
|
gptkb:HCV
gptkb:HIV
possible
long-term consequences
requires lifelong management
important in healthcare settings
|
|
gptkbp:duration
|
varies
|
|
gptkbp:epidemiology
|
global prevalence
|
|
gptkbp:fibrosis
|
can occur
|
|
gptkbp:flight_style
|
lipid envelope
|
|
gptkbp:healthcare_workers
|
at risk
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
HBV
|
|
gptkbp:infection_rates
|
vary by region
|
|
gptkbp:influenced_by
|
can help manage infection
|
|
gptkbp:is_involved_in
|
available for patients
|
|
gptkbp:is_monitored_by
|
liver function tests
viral load
|
|
gptkbp:is_vulnerable_to
|
gptkb:HBV_vaccine
high
|
|
gptkbp:liver_biopsy
|
used for assessment
|
|
gptkbp:liver_disease
|
liver cancer
cirrhosis
|
|
gptkbp:liver_transplant
|
possible treatment
|
|
gptkbp:long-term_follow-up
|
recommended for chronic patients
|
|
gptkbp:patient_education
|
important for prevention
|
|
gptkbp:post-exposure_prophylaxis
|
available
|
|
gptkbp:prevention
|
vaccination
|
|
gptkbp:public_awareness
|
needed for prevention
|
|
gptkbp:reprints
|
in hepatocytes
|
|
gptkbp:research
|
ongoing for better treatments
|
|
gptkbp:risk_factor
|
sharing needles
multiple sexual partners
unprotected sex
healthcare exposure
|
|
gptkbp:risk_of_transmission
|
higher during acute phase
|
|
gptkbp:scientific_classification
|
gptkb:World_Health_Organization
|
|
gptkbp:screenings
|
recommended for high-risk groups
|
|
gptkbp:seed_dispersal
|
circular DNA
|
|
gptkbp:serological_markers
|
HBs Ag
anti-HBc
anti-HBs
|
|
gptkbp:strategy
|
elimination by 2030
|
|
gptkbp:symptoms
|
fatigue
abdominal pain
jaundice
|
|
gptkbp:transmission
|
gptkb:blood
sexual contact
mother to child
|
|
gptkbp:treatment
|
antiviral medications
viral suppression
|
|
gptkbp:bfsParent
|
gptkb:HIV-2
|
|
gptkbp:bfsLayer
|
5
|